Ingredients Optimized partners with Supriya Lifescience expanding the manufacturing and distribution of its ioProtein to India
As part of the agreement, Supriya will lead the manufacturing and marketing of ioProtein in India.
Photo © AdobeStock.com/polesnoy
Ingredients Optimized announced a partnership with Supriya Lifescience Ltd. for the manufacture and distribution of Ingredient Optimized’ ioProtein ingredient in India. As part of the agreement, Supriya will lead the manufacturing and marketing of ioProtein in India.
"We are thrilled to be the exclusive partner of Plasma Nutrition, Inc. (Ingredient Optimized) in introducing the innovative ioProtein to the Indian market," said Dr. Saloni Wagh, executive director at Supriya Lifescience, in a press release. “This strategic partnership represents our commitment to providing high-nutrition solutions to consumers in India. With ioProtein's high bioavailability and its unmatched advantage, we are confident that the 'io' technology will revolutionize the nutrition industry and become the preferred choice for health-conscious individuals.”
"As finished protein products across India continue to innovate, we are excited to partner with Supriya Lifesciene to serve this market with our ioProteins” said Chris Flynn Rozanski, co-founder and CEO of Ingredient Optimized in a press release.
This partnership marks the latest effort by Ingredients Optimized to grow its market. In May, the company partnered with Pytho Therapy, an Australian distributor who helped launch Ingredients Optimized’s ioPea in three new products.
“Strengthening our global platform allows for new areas of innovation and product development with our ioProteins. Having science-based claims for enhanced absorption and bioavailability is a huge win for product development in the sports nutrition arena and we are excited to deliver that globally,” said Stephen Motosko, co-Founder and CEO of Ingredient Optimized in a press release.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
